GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Pretax Margin %
Switch to:

Biogen (BUE:BIIB) Pretax Margin %

: 17.80% (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Biogen's Pre-Tax Income for the three months ended in Mar. 2023 was ARS86,586 Mil. Biogen's Revenue for the three months ended in Mar. 2023 was ARS486,566 Mil. Therefore, Biogen's pretax margin for the quarter that ended in Mar. 2023 was 17.80%.

The historical rank and industry rank for Biogen's Pretax Margin % or its related term are showing as below:

BUE:BIIB' s Pretax Margin % Range Over the Past 10 Years
Min: 15.89   Med: 41.23   Max: 49.56
Current: 36.45


BUE:BIIB's Pretax Margin % is ranked better than
96.17% of 1044 companies
in the Drug Manufacturers industry
Industry Median: 3.60 vs BUE:BIIB: 36.45

Biogen Pretax Margin % Historical Data

The historical data trend for Biogen's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pretax Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.85 49.56 37.54 15.89 35.31

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Pretax Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.72 49.03 54.66 23.73 17.80

Biogen Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Biogen's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=602165.253/1705570.463
=35.31 %

Biogen's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=86586.167/486565.661
=17.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Biogen Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Biogen's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines